Notch Therapeutics Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced the closing of an oversubscribed U.S. $85 million Series A financing. Proceeds from the financing will support the continuing development of Notch’s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company’s proprietary Engineered Thymic Niche (ETN) platform.